US-based Medtronic has reportedly inked a deal with Ireland-based Covidien, a move that will lead to Medtronic to move its medical device manufacturing operations overseas.
Reports say Medtronic will acquire Covidien for $42.9 billion and move its executive base to Ireland. It’s part of a strategy by the US firm to reduce its tax burden, which will allow the company to allocate more funds for US investment, the company said.
The merger will also establish a greater competitor to current medical device behemoth Johnson & Johnson. The acquisition of Covidien will expand Medtronic’s medical device portfolio into weight-loss surgery and other services, according to reports.
The deal remains subject to regulatory approval.
In related news, the European Commission recently announced plans to investigate three member states, including Ireland, and their tax relationships with major companies including Starbucks and Apple.
Full content: Irish Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI